Published in Elder Law Weekly, June 1st, 2005
Additionally, mild Alzheimer disease patients who achieved high plasma concentrations of Flurizan demonstrated a statistically significant effect in two of the three primary endpoints. The initial findings also indicate that Flurizan was well tolerated in this 12-month, 207 patient clinical study.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.